TABLE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

dataset

posted on 2023-06-05, 14:20 authored by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana

Table showing 14 inhibitors tested in combination with ZKN-157. Combination effects were color coded blue (synergism) or orange (antagonism) according to the scores obtained from the BI analysis

Funding

n/a

History

ARTICLE ABSTRACT

This study demonstrates that ribosome heterogeneity in cancer can be exploited to develop selective ribogenesis inhibitors. The colorectal cancer CMS2 subtype, with a high unmet need for therapeutics, shows vulnerability to our novel selective ribosome modulator. The mechanism suggests that other cancer subtypes with high MYC activation could also be targeted.